Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 29OTHER 22NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Specimen Handling 116Magnetic Resonance Spectroscopy 78Biopsy 69Cyclophosphamide 24pembrolizumab 22Cisplatin 21fludarabine 18Platinum 171,2-diaminocyclohexaneplatinum II citrate 17Taxes 16Paclitaxel 16Carboplatin 16Nivolumab 15Immunoglobulin G 14Disulfides 14X-Rays 13Radiation 13Doxorubicin 12venetoclax 11Radiotherapy 11Gemcitabine 11durvalumab 9cabozantinib 8aldesleukin 8Prednisone 8atezolizumab 7Cytarabine 7olaparib 6lutetium Lu 177 dotatate 6gallium Ga 68 dotatate 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × NIH × ribociclib × Clear all
NCT07391774 2026-06-05

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

National Cancer Institute (NCI)

Phase 3 Recruiting
1,978 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡